1. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
   Haibo Zhu et al, 2021, OncoTargets and Therapy CrossRef
2. Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report
   Cang-Jian Zhang et al, 2022, World Journal of Clinical Cases CrossRef
3. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
   Xiaomin Zhang et al, 2022, Frontiers in Immunology CrossRef
4. Knowns and Unknowns about CAR-T Cell Dysfunction
   Aleksei Titov et al, 2022, Cancers CrossRef
5. Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report
   Zhi-Yun Niu et al, 2021, World Journal of Clinical Cases CrossRef
6. Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review
   Gang Feng et al, 2021, Frontiers in Oncology CrossRef
7. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies
   I-Tsu Chyuan et al, 2021, Cancers CrossRef
8. Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials
   Shan Li et al, 2020, OncoImmunology CrossRef
9. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
   Chunyi Shen et al, 2020, BioMed Research International CrossRef
10. Research progress in the PD-1/PD-L1 pathway and IL-17A in lymphomas
    null null et al, 2022, Aging Pathobiology and Therapeutics CrossRef
11. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
    Yun Liang et al, 2021, Journal of Hematology & Oncology CrossRef
12. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
    Xinyi Xiao et al, 2022, Frontiers in Immunology CrossRef
13. Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
    Sophia Stock et al, 2022, Biomedicines CrossRef